

Special Issue

Molecular Research on Non-small Cell Lung Cancer

Message from the Guest Editor

This Special Issue focuses on "Molecular Research on Non-Small Cell Lung Cancer". Recently, various oncogenes have been found to be overexpressed in NSCLC and highly correlated with aggressiveness, epithelial-to-mesenchymal transition, and chemoresistance, since they transduce multiple signals for cell growth, survival, proliferation, invasion, migration, angiogenesis, and inhibition of apoptosis. Therefore, customized therapy targeting these oncogenes may be a potent and practical target for the successful treatment of NSCLC, and this will be the focus of this Special Issue. Review manuscripts as well as original investigations demonstrating novel therapeutic targets and candidates to be tested in clinical trials and the underlying molecular mechanisms and crosstalk of signaling with other signaling pathways will be considered for publication.

Guest Editor

Dr. Chuhee Lee

Department of Biochemistry and Molecular Biology, School of Medicine, 170 Hyun-Chung Ro, Yeungnam University, Daegu 42415, Republic of Korea

Deadline for manuscript submissions

closed (30 April 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/103717

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).